Clinical Diagnostics Technology & Disease Research News | 360Dx
WEBThe test assigns a pancreatic cancer subtype based on the expression of 16 genes measured using an array. Hedera Dx Expects Increased Liquid Biopsy Adoption With Real-World Data Cancer Registries. Following a lung cancer study, the firm plans to initiate similar studies in other cancers and to launch a new tumor profiling assay later this year.
FDA to Reclassify Hepatitis B Virus Tests as Moderate Risk Devices
WEB1 day ago · NEW YORK – The US Food and Drug Administration said on Tuesday that it plans to reclassify several types of qualitative and quantitative hepatitis B virus (HBV) tests as moderate risk class II devices from their current classification as high-risk class III devices. The FDA said on the Federal Register's website that it plans to publish on ...
As Digital Pathology Slowly Expands, Industry Anxiously Awaits a ...
WEB1 day ago · NEW YORK – Though only a minority of pathology labs have so far added digital slide scanning and analysis technologies, pathologists and companies in the space see slow but continued growth in the market and the potential for a breakout moment that would bring widespread adoption. This year, firms have announced plans to , using those ...
Protean BioDiagnostics to Market Nanostics Prostate Cancer Risk …
WEB1 day ago · NEW YORK — Protean BioDiagnostics has signed an agreement to market Nanostics' prostate cancer risk assessment tool in the US, the companies said on Tuesday. Called ClarityDx Prostate, the tool analyzes two blood-based biomarkers — total prostate-specific antigen (PSA) and free PSA — and up to five clinical features including patient age ...
Labcorp Closes $2B Senior Notes Public Offering | 360Dx
WEB1 day ago · Save for later. NEW YORK – Laboratory Corporation of America has closed its $2.0 billion public offering of senior notes, it said on Tuesday in a document filed with the US Securities and Exchange Commission. The firm said it has entered into a base indenture and supplemental indentures with US Bank for $2.0 billion in debt securities.
About Us - 360Dx
WEBAbout Us. 360Dx is published by GenomeWeb, an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and diagnostics. GenomeWeb is a family brand of Crain ...
Foundation Medicine Nabs Five-Year VA Contract for Tumor …
WEB1 day ago · NEW YORK – Roche subsidiary Foundation Medicine announced Tuesday that it has received a five-year contract from the US Department of Veterans Affairs to provide tumor molecular profiling tests to veterans with cancer. The contract is part of the VA's National Precision Oncology Program and covers ...
Breaking News - 360Dx
WEBSep 18, 2024 · Labcorp Acquires $190M Stake in European Testing Firm SYNLAB, Prices $2B Senior Notes Offering. Labcorp will hold a 15 percent indirect minority stake in SYNLAB, which operates in more than 30 countries and performed roughly 600 million tests in 2023. Sep 17, 2024.
Diagnostic Technologies and Applications - 360Dx
WEBHedera Dx Expects Increased Liquid Biopsy Adoption With Real-World Data Cancer Registries. Following a lung cancer study, the firm plans to initiate similar studies in other cancers and to launch a new tumor profiling assay later this year. The test assigns a pancreatic cancer subtype based on the expression of 16 genes measured using an array.
Precision Oncology Specialties News - 360Dx
WEBCancer Diagnostics Firm Syantra Raises $3.6M in Series A-1 Round. The University of Calgary spinout aims to commercialize a liquid biopsy test that measures mRNA biomarkers for the early detection of breast cancer. Get the latest news on cancer diagnostics, liquid biopsy, and cancer risk testing from 360Dx.